Table 3.
Cox regression analysis for progression-free survival (N = 40)
| Variables | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p value | HR | 95% CI | p value | |
| Age at diagnosis, years (≤ 60 vs > 60) | 1.277 | 0.484–3.368 | 0.622 | |||
| Location (left vs right) | 1.219 | 0.547–2.716 | 0.629 | |||
| HER2 status (IHC 3+ vs IHC2+ and FISH+) | 1.017 | 0.355–2.687 | 0.972 | |||
| Hormone-receptor status (ER and/or PR positive vs ER and PR negative) | 0.639 | 0.299–1.367 | 0.248 | |||
| Previous anti-HER2 antibody treatment in metastatic setting (yes vs no) | 0.947 | 0.225–4.037 | 0.953 | |||
| Previous anti-HER2 TKI treatment (yes vs no) | 0.958 | 0.451–2.033 | 0.911 | |||
| Brain metastases (yes vs no) | 1.877 | 0.843–4.179 | 0.123 | |||
| Liver or/and lung metastases (yes vs no) | 0.322 | 0.132–0.831 | 0.018 | 0.281 | 0.093–0.876 | 0.026 |
| Number of previous treatment lines (≤ 2 vs > 2) | 1.190 | 0.548–2.585 | 0.660 | |||
| Combined chemotherapeutic drug (Vinorelbine vs Cepecitabine vs Nab-paclitaxel) | 1.197 | 0.834–1.717 | 0.329 | |||
HR hazard ratio, CI confidence interval, HER2 human epidermal growth factor receptor, IHC immunohistochemistry, FISH fluorescence in situ hybridization, ER estrogen receptor, PR progesterone receptor, TKI tyrosine kinase inhibitor